112 related articles for article (PubMed ID: 22801957)
1. Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs.
Dasanu CA
J Oncol Pharm Pract; 2012 Sep; 18(3):379-80. PubMed ID: 22801957
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
3. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
5. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
6. The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.
Eisenberg BL
Am J Clin Oncol; 2013 Feb; 36(1):89-90. PubMed ID: 23334483
[TBL] [Abstract][Full Text] [Related]
7. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
Blay JY; Rutkowski P
Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
Pisters PW; Colombo C
J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
12. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
13. Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit.
Prescrire Int; 2011 Mar; 20(114):61-3. PubMed ID: 21648223
[TBL] [Abstract][Full Text] [Related]
14. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
[TBL] [Abstract][Full Text] [Related]
15. Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
Pulido EG; Riquelme A; Ballesteros J; Vaz MÁ
Anticancer Drugs; 2012 Jun; 23 Suppl():S15-7. PubMed ID: 22739666
[TBL] [Abstract][Full Text] [Related]
16. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
Saad Aldin E; Mourad F; Tfayli A
Jpn J Clin Oncol; 2012 May; 42(5):447-50. PubMed ID: 22422898
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
[TBL] [Abstract][Full Text] [Related]
18. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors.
Blay JY; Pérol D; Le Cesne A
Ann Oncol; 2012 Jul; 23(7):1659-65. PubMed ID: 22357253
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
Walker EJ; Simko JP; Ko AH
Anticancer Res; 2014 Jul; 34(7):3629-34. PubMed ID: 24982379
[TBL] [Abstract][Full Text] [Related]
20. Imatinib treatment of metastatic GIST: don't stop (believing).
Heinrich MC
Lancet Oncol; 2010 Oct; 11(10):910-1. PubMed ID: 20864404
[No Abstract] [Full Text] [Related]
[Next] [New Search]
